In vitro, LL‑37 showed no significant antimicrobial activity against cystic fibrosis isolates of S. aureus, P. aeruginosa and S. maltophilia (MIC50 above 32 μg/ml).
In plain wordsIn lab tests, LL‑37 did not kill bacteria taken from cystic fibrosis lungs at the doses tested.
- Peptide
- LL-37
- Outcome
- No significant changeAntibacterial activity (MIC50) against cystic fibrosis isolates
- Study
S. aureus, P. aeruginosa, S. maltophilian: not reported in source
Strains isolated from cystic fibrosis patients- Comparator
- Tobramycin
- Outcome group
- Infection and antimicrobial activity · Infection
- Studied dose
- Dose not stated
Measurements
- MIC50
- > 32 μg/ml
- cystic fibrosis isolates
Source sentences
In contrast, indolicidin, LL-37, and Bac7(1-35) showed no significant antimicrobial activity (MIC(50)>32μg/ml).
1 context sentence(design, population, supporting numbers)
Six different cathelicidin-derived peptides were compared to tobramycin for antibacterial and anti-biofilm effects against S. aureus, P. aeruginosa, and S. maltophilia strains isolated from cystic fibrosis patients.